RT Journal Article
SR Electronic
T1 Gestational trophoblastic tumors: cytostatic treatment response evaluated from hCG modelling
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 265
OP 270
DO 10.1046/j.1525-1438.1993.03050265.x
VO 3
IS 5
A1 C. TropÉ
A1 J. Carl
YR 1993
UL http://ijgc.bmj.com/content/3/5/265.abstract
AB Five patients, three high risk and two medium risk, were allocated to a high dose methotrexate regimen. Surviving fractions of hCG-producing cells in high dose methotrexate were a factor of 3–10 times lower than the surviving cell fractions in the low dose regimen, indicating a biphasic dose-response relation for methotrexate. Medium risk patients were found to have an unacceptably high recurrence rate after methotrexate actinomycin-D therapy and should be treated with more intensive chemotherapy. It is recommended that drug dose should be corrected for body-volume in low risk regimes, to avoid drug resistance developing because of increased treatment time.